95841-14-8

Basic information

• Product Name: (4R,5S)-3-(3-phenylpropionyl)-4-methyl-5-phenyl-oxazolidin-2-one
• Synonyms: (4R,5S)-3-(3-phenylpropionyl)-4-methyl-5-phenyl-oxazolidin-2-one
• CAS NO: 95841-14-8
• Molecular Weight: 309.365
• Mol File: 95841-14-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (4R,5S)-3-(3-phenylpropionyl)-4-methyl-5-phenyl-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4R,5S)-3-(3-phenylpropionyl)-4-methyl-5-phenyl-oxazolidin-2-one(95841-14-8)
• EPA Substance Registry System: (4R,5S)-3-(3-phenylpropionyl)-4-methyl-5-phenyl-oxazolidin-2-one(95841-14-8)

Safety Data

• Hazardous Substances Data: 95841-14-8(Hazardous Substances Data)

Upstream product

• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 25145-43-1 2-phenylpropionyl chloride 
• 591733-72-1 (4R,5S)-(+)-4-methyl-5-phenyloxazolidin 
• 645-45-4 hydrocinnamic acid chloride 

Downstream Products

• 257277-36-4 (4R,5S)-3-{(R)-2-[N,N'-bis-(tert-butoxycarbonyl)hydrazino]-3-phenylpropanoyl}-4-methyl-5-phenyl-1,3-oxazolidin-2-one 
• 131288-24-9 (4R,5S)-3[(2S)-3t-butoxycarbonyl-2-benzylpropionyl]-4-methyl-5-phenyl-oxazolidine-2-one 
• 105943-89-3 (4S,5S)-3-<(2S)-2-benzyl-3-(benzyloxy)propionyl>-4-methyl-5-phenyloxazolidinone 
• 151647-54-0 3-phenyl-1-pyrrolidin-1-yl-propane-1-one 
• 501-52-0 3-Phenylpropionic acid 
• 10264-11-6 N‐butyl‐3‐phenylpropanamide 
• 2021-28-5 ethyl dihydrocinnamate 
• 134458-74-5 (2R,3R,4R,5S)-2-Benzyl-3,4-dihydroxy-5-{(S)-3-(1H-imidazol-4-yl)-2-[2-(naphthalen-1-yloxy)-acetylamino]-propionylamino}-6-phenyl-hexanoic acid {(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide 
• 134458-71-2 3(R)-<3-(tert-butyloxycarbonyl)-4(S)-phenylmethyl-2,2-dimethyl-5(R)-oxazolidinyl>-3-hydroxy-2(R)-(phenylmethyl)propanoic acid 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 

Relevant articles and documents

Fluorinated Pseudopeptide Analogues of the Neuropeptide 26RFa: Synthesis, Biological, and Structural Studies

A series of four fluorinated dipeptide analogues each containing a fluoro-olefin moiety as peptide bond surrogate has been designed and synthesized. These motifs have been successfully introduced into the bioactive C-terminal heptapeptide of the neuropeptide 26RFa by conventional SPPS. We then evaluated the ability of the generated pseudopeptides to increase [Ca2+]i in GPR103-transfected cells. For these fluorinated analogues, greater stability in human serum was observed. Their conformations were also investigated, leading to the valuable identification of differences depending on the position of the fluoro-olefin moiety in the sequence.

Renin inhibitors having all retro-inverted peptide bonds

Renin-inhibiting peptides of the formula STR1 in which X represents a group of the formula STR2 represents hydroxyl, alkoxy having up to 8 carbon atoms, benzyloxy or a group of the formula --NR4 R5, A, B, D and E are identical or different and in each case represent a direct bond, represent a radical of the formula STR3 in which Q1 denotes oxygen, sulphur or the methylene group represent a grouping of the formula STR4 m represents a number 0, 1 or 2, and L represents a group of the formula --CH2 NR2 R3 and physiologically acceptable salts thereof.

Asymmetric synthesis of the enkephalinase inhibitor thiorphan

-